Seladelpar 是一种 PPAR-delta 激动剂,在 3 期研究中显示出对原发性胆汁性胆管炎 (PBC) 的安全性和改善作用。 Seladelpar, a PPAR-delta agonist, shows safety and improvement in primary biliary cholangitis (PBC) in a phase 3 study.
Seladelpar 显示原发性胆汁性胆管炎 (PBC) 患者的肝损伤和瘙痒标志物得到“持续改善”,在正在进行的 3 期 ASSURE 研究中,70% 的患者达到了主要研究终点,37.2% 的患者碱性磷酸酶恢复正常。 Seladelpar shows 'sustained improvement' in liver injury and pruritis markers in primary biliary cholangitis (PBC) patients, with 70% achieving primary study endpoint and 37.2% normalizing alkaline phosphatase in ongoing phase 3 ASSURE study. Seladelpar 是一种 PPAR-delta 激动剂,在第 12 个月内表现出安全性和耐受性,胆汁淤积和肝损伤标志物具有临床意义的改善。 Seladelpar, a PPAR-delta agonist, demonstrates safety and tolerability through month 12, with clinically meaningful improvements in cholestasis and liver injury markers.